Inotropic effects of prokinetic agents with 5-HT4 receptor agonist actions on human isolated myocardial trabeculae

Life Sciences

Volumn 90, Issue 13-14, 2012, Pages 538-544

  Chai, Wenxia ^a   Chan, Kayi Y ^a   De Vries, René ^a   Van Den Bogeardt, Antoon J ^a   De Maeyer, Joris H ^b   Schuurkes, Jan A J ^b   Villalón, Carlos M ^c   Saxena, Pramod R ^a   Danser, A H Jan ^a   Maassenvandenbrink, Antoinette ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Movetis NV   (Belgium)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

5 HT; Atrium; Contractility; Gastrointestinal prokinetic agents

Indexed keywords

5 METHOXYTRYPTAMINE; CALCIUM CHANNEL L TYPE; CISAPRIDE; DRUG METABOLITE; NORADRENALIN; PRUCALOPRIDE; SEROTONIN; TEGASEROD; VERAPAMIL;

ADULT; AGED; ATTENUATION; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HEART ATRIUM; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE CONTRACTILE FORCE; HEART VENTRICLE; HUMAN; HUMAN TISSUE; INOTROPISM; MALE; OUTCOME ASSESSMENT; PARTIAL AGONISM; REVIEW; SCHOOL CHILD;

EID: 84859110115     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.01.009     Document Type: Article

References (45)

1. 4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles Br J Pharmacol 155 2008 1005 1014
2. 4 receptor partial agonist with promotile activity Clin Pharmacokinet 41 2002 1021 1042 (Pubitemid 35246780)
3. S. Appel-Dingemanse, Y. Hirschberg, S. Osborne, F. Pommier, and J. McLeod Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919) Eur J Clin Pharmacol 56 2001 889 891 (Pubitemid 33788565)
4. 4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle Naunyn Schmiedebergs Arch Pharmacol 363 2001 146 160 (Pubitemid 32200322)
5. 2B receptor antagonist in vitro and in vivo Br J Pharmacol 143 2004 549 560 (Pubitemid 39524272)
6. 4 receptor partial agonist for irritable bowel syndrome Int J Clin Pract 56 2002 47 51 (Pubitemid 34100537)
7. 4 receptor antagonist in heart failure Br J Pharmacol 150 2007 143 152 (Pubitemid 46160604)
8. 4 receptor splice variant, 5-HT4(i) Naunyn Schmiedebergs Arch Pharmacol 369 2004 616 628 (Pubitemid 38823994)
9. K.Y. Chan, R. de Vries, F.P. Leijten, H.J. Pfannkuche, A.J. van den Bogaerdt, and A.H. Danser Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries Eur J Pharmacol 619 2009 61 67
10. 3 agonist MKC-733 on the rat, mouse and guinea pig digestive tract Pharmacology 81 2008 104 109 (Pubitemid 351182684)
11. 4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior J Pharmacol Exp Ther 317 2006 955 964 (Pubitemid 43764097)
12. J.H. De Maeyer, R. Straetemans, J.A. Schuurkes, and R.A. Lefebvre Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development Br J Pharmacol 147 2006 140 157 (Pubitemid 43151562)
13. C.L. Devlin 5-Hydroxytryptamine stimulates net Ca2 + flux in the ventricular muscle of a mollusc (Busycon canaliculatum) during cardioexcitation Biol Bull 200 2001 344 350 (Pubitemid 32554725)
14. S. Evangelista Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease Curr Opin Investig Drugs 8 2007 416 422 (Pubitemid 46700998)
15. E. Farrington Cardiac toxicity with cisapride Pediatr Nurs 22 1996 256
16. J.J. Galligan, and S. Vanner Basic and clinical pharmacology of new motility promoting agents Neurogastroenterol Motil 17 2005 643 653 (Pubitemid 41400712)
17. D. Hoyer, J.P. Hannon, and G.R. Martin Molecular, pharmacological and functional diversity of 5-HT receptors Pharmacol Biochem Behav 71 2002 533 554 (Pubitemid 34219205)
18. U. Jahnel, J. Rupp, R. Ertl, and H. Nawrath Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle Naunyn Schmiedebergs Arch Pharmacol 346 1992 482 485
19. 4 receptors by GR 113808 Br J Pharmacol 110 1993 1172 1174 (Pubitemid 24005256)
20. A.J. Kaumann, and F.O. Levy 5-hydroxytryptamine receptors in the human cardiovascular system Pharmacol Ther 111 2006 674 706 (Pubitemid 44118434)
21. 4 receptors in human atrium: facilitation by chronic beta-adrenoceptor blockade Naunyn Schmiedebergs Arch Pharmacol 349 1994 331 337 (Pubitemid 24110202)
22. 4-like receptor in human right atrium Naunyn Schmiedebergs Arch Pharmacol 344 1991 150 159
23. 4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure Eur J Heart Fail 11 2009 771 778
24. 4 splice variants Naunyn Schmiedebergs Arch Pharmacol 371 2005 473 479 (Pubitemid 41218967)
25. 1B/1D receptor antagonist GR55562 Pharmacol Toxicol 86 2000 287 290 (Pubitemid 30413406)
26. R.W. McCallum, C. Prakash, D.M. Campoli-Richards, and K.L. Goa Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders Drugs 36 1988 652 681 (Pubitemid 19002884)
27. S. Mohammad, Z. Zhou, Q. Gong, and C.T. January Blockage of the HERG human cardiac K + channel by the gastrointestinal prokinetic agent cisapride Am J Physiol 273 1997 H2534 H2538
28. J. Morganroth, P.C. Ruegg, C. Dunger-Baldauf, S. Appel-Dingemanse, H. Bliesath, and M. Lefkowitz Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects Am J Gastroenterol 97 2002 2321 2327
29. H. Ouadid, J. Seguin, A. Dumuis, J. Bockaert, and J. Nargeot Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors Mol Pharmacol 41 1992 346 351
30. D. Pau, A.J. Workman, K.A. Kane, and A.C. Rankin Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic beta-adrenoceptor blockade Br J Pharmacol 140 2003 1434 1441 (Pubitemid 38067850)
31. D. Pau, A.J. Workman, K.A. Kane, and A.C. Rankin Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists J Pharmacol Exp Ther 313 2005 146 153 (Pubitemid 40411338)
32. 4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes Cardiovasc Res 40 1998 516 522 (Pubitemid 28557292)
33. D. Pohl, R. Tutuian, and M. Fried Pharmacologic treatment of constipation: what is new? Curr Opin Pharmacol 8 2008 724 728
34. F. Potet, T. Bouyssou, D. Escande, and I. Baro Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel J Pharmacol Exp Ther 299 2001 1007 1012 (Pubitemid 33104972)
35. Y. Sakurai-Yamashita, K. Yamashita, M. Yoshimura, and K. Taniyama Differential localization of 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors in the human rectum Life Sci 66 2000 31 34 (Pubitemid 30025446)
36. R.G. Schoemaker, X.Y. Du, W.A. Bax, and P.R. Saxena 5-Hydroxytryptamine increases contractile force in porcine right atrium but not in left ventricle Naunyn Schmiedebergs Arch Pharmacol 346 1992 486 489
37. R.G. Schoemaker, X.Y. Du, W.A. Bax, E. Bos, and P.R. Saxena 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle Eur J Pharmacol 230 1993 103 105 (Pubitemid 23024988)
38. C.E. Sloots, A.C. Poen, R. Kerstens, M. Stevens, M. De Pauw, and J.C. Van Oene Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation Aliment Pharmacol Ther 16 2002 759 767 (Pubitemid 34407524)
39. S.K. Swan, H. Zhou, A. Horowitz, L. Alladina, M. Hubert, and S. Appel-Dingemanse Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects J Clin Pharmacol 43 2003 359 364 (Pubitemid 36368778)
40. J. Tack, M. van Outryve, G. Beyens, R. Kerstens, and L. Vandeplassche Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives Gut 58 2009 357 365
41. C.A. Thompson Novartis suspends tegaserod sales at FDA's request Am J Health Syst Pharm 64 2007 1020 (Pubitemid 46801527)
42. M. Tonini, F. De Ponti, A. Di Nucci, and F. Crema Review article: cardiac adverse effects of gastrointestinal prokinetics Aliment Pharmacol Ther 13 1999 1585 1591 (Pubitemid 30009075)
43. J.M. Van Nueten, and J.A. Schuurkes Development of a new gastrointestinal prokinetic; pharmacology of cisapride J Pharm Belg 46 1991 17 22
44. L.R. Wiseman, and D. Faulds Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders Drugs 47 1994 116 152 (Pubitemid 24032381)
45. D.K. Wysowski, and J. Bacsanyi Cisapride and fatal arrhythmia N Engl J Med 335 1996 290 291